Study guide

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis

Key Takeaways Explain This Topic AI

Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations span six distinct molecular classes, with Class II (F508del trafficking defect) representing ~85–90% of affected alleles, followed by Class III gating defects (G551D), Class I synthesis defects, Class IV conduction defects (R117H), and Class V splicing mutations.

Newborn screening couples immunoreactive trypsinogen (IRT) with targeted DNA mutation panels; confirmation requires quantitative pilocarpine iontophoresis sweat chloride testing, where values ≥60 mmol/L are diagnostic of cystic fibrosis, 30–59 mmol/L represent an intermediate/borderline zone requiring repeat testing and expanded gene sequencing, and <30 mmol/L are normal.

Loss of CFTR chloride and bicarbonate secretion alongside ENaC hyperactivation dehydrates the airway surface liquid (ASL), creating viscous mucus stasis, hypoxic microenvironments, persistent neutrophilic inflammation, and progressive bronchiectasis.

Inhaled airway clearance therapy follows a mandatory 5-step sequence: 1. Inhaled bronchodilator (albuterol) → 2. Hypertonic saline 7% (osmotic hydration) → 3. Dornase alfa (Pulmozyme 2.5 mg daily via approved jet nebulizer; cleaves neutrophil DNA) → 4. Airway clearance therapy (chest physiotherapy / oscillating vest) → 5. Inhaled antipseudomonal antibiotics (tobramycin, aztreonam, colistimethate).

Dornase alfa (Pulmozyme) must never be mixed or admixed with any other medication in the nebulizer cup, requires refrigeration (2–8°C) protected from light, and must be administered prior to chest physiotherapy, while inhaled antibiotics must strictly be administered LAST after airway clearance.

Last updated: September 2026

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive genetic disorder among individuals of Northern European descent, affecting approximately 1 in 3,000 live births. It is caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, located on the long arm of chromosome 7 (7q31.2). The CFTR protein functions as an apical cyclic adenosine monophosphate (cAMP)-dependent and protein kinase A (PKA)-activated epithelial anion channel that facilitates the transport of chloride (Cl⁻) and bicarbonate (HCO₃⁻) across epithelial membranes throughout the respiratory, gastrointestinal, hepatobiliary, reproductive, and sweat gland systems. Loss of functional CFTR leads to multi-organ pathology characterized by desiccated secretions, chronic endobronchial infection, progressive bronchiectasis, and exocrine pancreatic insufficiency.

Molecular Pathophysiology & CFTR Mutation Classes

The CFTR protein consists of 1,480 amino acids comprising two membrane-spanning domains (MSD1 and MSD2) that form the channel pore, two nucleotide-binding domains (NBD1 and NBD2) that bind and hydrolyze ATP, and a regulatory (R) domain containing multiple phosphorylation sites. Over 2,100 individual mutations in the CFTR gene have been identified. To guide prognosis and molecularly targeted therapeutics, these mutations are categorized into six functional classes based on the primary molecular defect:

Mutation Class Molecular Mechanism Cellular Defect Prototypic Mutation CFTR Protein at Apical Membrane Phenotypic Severity

Class I Defective protein synthesis Premature termination codons (nonsense mutations), frame-shifts, or large deletions yielding truncated mRNA G542X, W1282X, R553X Absent (0%) Severe (classic CF, early pancreatic insufficiency)

Class II Defective protein processing & trafficking Protein misfolding in endoplasmic reticulum (ER); rapid ubiquitination and premature proteasomal degradation F508del (deletion of phenylalanine at codon 508), N1303K Severely reduced (<1% reaches membrane) Severe (classic CF; accounts for ~85–90% of CF alleles in North America)

Class III Defective channel gating & regulation Channel reaches apical membrane normally, but ATP binding/hydrolysis fails to open the pore ("closed gate") G551D, G1244E, S549N Normal membrane density; zero channel open probability (Po) Severe (classic CF, pancreatic insufficiency)

Class IV Defective channel conductance Missense mutations in pore-lining residues reduce the rate of chloride and bicarbonate ion transit R117H, R334W, R347P Normal membrane density; reduced ion flux per open channel Mild-to-moderate (often pancreatic sufficient; variable pulmonary disease)

Class V Reduced protein synthesis / abnormal splicing Splicing defects or promoter mutations produce reduced amounts of normal, functional CFTR transcripts 3849+10kbC→T, A455E Reduced membrane density (typically 5–10% of normal); normal gating Mild-to-moderate (often adult presentation, pancreatic sufficient)

Class VI Accelerated cell surface turnover CFTR reaches the apical surface but exhibits extreme instability, with accelerated endocytosis and degradation 4326delTC, rescued F508del Markedly reduced half-life at the plasma membrane Variable severity CFTR Mutation Classification Architecture:

  • Nucleus / DNA ───────► Class I: Defective Synthesis (e.g., G542X)
  • │
  • Endoplasmic Reticulum ─► Class II: Processing / Trafficking Block (e.g., F508del)
  • │
  • Golgi / Trafficking ───► Class V: Splicing / Reduced Quantity (e.g., 3849+10kbC->T)
  • │
  • Apical Membrane ──────┬─► Class III: Gating Defect (e.g., G551D)
  • ├─► Class IV: Conduction Defect (e.g., R117H)
  • └─► Class VI: Membrane Instability / Turnover (e.g., 4326delTC)
  • Newborn Screening & Diagnostic Sweat Chloride Testing
  • Newborn Screening (NBS) Algorithm

Universal newborn screening for CF is standard across all 50 US states. The initial screening test utilizes dried blood spots collected on filter paper (Guthrie card) between 24 and 48 hours of life to quantify immunoreactive trypsinogen (IRT) via radioimmunoassay or enzyme-linked immunosorbent assay (ELISA). In utero pancreatic ductal obstruction causes retrograde leakage of pancreatic zymogens into fetal circulation, resulting in markedly elevated serum IRT levels at birth.

Two primary secondary algorithms are utilized:

IRT / DNA: An elevated IRT (e.g., top 4–5th percentile) automatically triggers second-tier genetic analysis using a panel of the 30 to 100+ most prevalent CFTR mutations (including F508del). If one or two mutations are detected, the infant is referred for diagnostic sweat chloride testing.

IRT / IRT: If genetic testing is not immediately available, a repeat IRT is obtained at 2 to 3 weeks of life. Persistently elevated IRT mandates sweat testing.

Sweat Chloride Testing: Quantitative Pilocarpine Iontophoresis

The gold standard confirmatory diagnostic test is quantitative sweat chloride determination using pilocarpine iontophoresis (the Gibson-Cooke method or the modern Wescor Macroduct system). Pilocarpine is driven into the skin using a low-voltage electrical current to stimulate local eccrine sweat glands. Sweat is collected over a strict 30-minute interval, and chloride concentration is quantified in millimoles per liter (mmol/L).

To ensure diagnostic accuracy, strict physiological and technical thresholds must be fulfilled:

Minimum sweat collection weight/volume: ≥75 mg of sweat (Gibson-Cooke) or ≥15 μL (Macroduct system). Sweat collection rates <1 g/m²/min produce artifactually concentrated sweat and invalid results.

Patient Age: Infants should ideally be at least 48 hours old and clinically stable; testing is most reliable between 2 and 4 weeks of life.

Sweat Chloride Concentration (mmol/L) Clinical Interpretation Recommended Next Diagnostic Step

≥60 mmol/L Diagnostic of Cystic Fibrosis Confirms diagnosis on 2 independent occasions; initiate comprehensive multidisciplinary CF care.

30 to 59 mmol/L Intermediate / Borderline (Possible CF or CFTR-related disorder) Repeat sweat chloride test; perform comprehensive CFTR gene sequencing with deletion/duplication analysis; consider functional testing (nasal potential difference [NPD] or intestinal current measurement [ICM]).

<30 mmol/L Normal / Negative (CF highly unlikely) CF ruled out in >99% of cases; investigate alternative pulmonary/gastrointestinal etiologies.

Important

Diagnostic Criteria for CF: Confirmation of cystic fibrosis requires characteristic clinical features (respiratory, gastrointestinal, or reproductive), a positive newborn screen, or a family history of CF in a sibling, PLUS laboratory evidence of CFTR dysfunction demonstrated by: (1) sweat chloride ≥60 mmol/L on two separate occasions; OR (2) identification of two disease-causing CFTR mutations in trans (one on each parental allele); OR (3) characteristic transepithelial nasal potential difference (NPD) abnormalities.

The Pathophysiologic Cascade: Dehydration to Bronchiectasis

In healthy airway epithelia, CFTR actively secretes chloride and bicarbonate into the airway lumen while tonically inhibiting the epithelial sodium channel (ENaC) . This coordinated ion transport maintains a hydrated periciliary liquid (PCL) layer approximately 7 micrometers (μm) in depth, allowing cilia to beat synchronously at 10 to 15 Hz to clear inhaled pathogens, cellular debris, and mucus.

In CF airway epithelia, loss of CFTR function produces three catastrophic biophysical shifts:

Loss of Apical Chloride and Bicarbonate Efflux: Chloride cannot exit the cell, and bicarbonate secretion is extinguished. The absence of bicarbonate impairs normal mucin unpacking, leading to compact, poorly expanding mucus polymers.

Unchecked ENaC Hyperactivity: Loss of tonic CFTR-mediated inhibition results in profound ENaC hyperactivation. Sodium (Na⁺) is hyperabsorbed from the airway lumen into the epithelial cell, drawing water osmotically along its concentration gradient.

Airway Surface Liquid (ASL) Dehydration: The PCL layer collapses to <2 μm , physically trapping and flattening the ciliated axonemes against the epithelial surface. Mucociliary clearance ceases completely. Pathophysiologic Cascade in the CF Airway:

  • [Absent / Defective CFTR Channel]
  • │
  • ├──────────────────────────────┐
  • ▼ ▼
  • Impaired Cl⁻ & HCO₃⁻ Efflux Unchecked ENaC Hyperactivation
  • │ │
  • └──────────────┬───────────────┘
  • ▼
  • Massive Luminal Na⁺ & Water Reabsorption
  • ▼
  • Airway Surface Liquid (ASL) Dehydration
  • ▼
  • Periciliary Layer Collapse (<2 µm) & Ciliary Failure
  • ▼
  • Mucus Stasis, Plugging & Hypoxic Plugs
  • ▼
  • Bacterial Colonization (S. aureus, H. flu, P. aeruginosa)
  • ▼
  • Massive Neutrophil Influx ──► Extracellular DNA Release (NETs)
  • ▼
  • Neutrophil Elastase Release ──► Elastin & Collagen Lysis
  • ▼
  • BRONCHIECTASIS, FIBROSIS & END-STAGE LUNG FAILURE

Trapped, desiccated mucus forms intraluminal plugs that create anaerobic microenvironments. Early colonization with Staphylococcus aureus and Haemophilus influenzae triggers a massive, dysregulated host inflammatory response dominated by polymorphonuclear neutrophils (PMNs) . Unlike in healthy lungs where neutrophils phagocytose bacteria and undergo apoptosis, CF neutrophils undergo necrotic lysis, releasing massive quantities of high-molecular-weight extracellular DNA (neutrophil extracellular traps [NETs]) , actin filaments, and proteolytic enzymes, specifically neutrophil elastase .

This extracellular DNA forms an extensive cross-linked macromolecular matrix that escalates sputum viscosity by orders of magnitude. Simultaneously, uninhibited neutrophil elastase degrades structural elastin and collagen fibers in the bronchial walls, destroys local opsonins and immunoglobulins, and cleaves epithelial tight junctions. The irreversible destruction of muscular and elastic tissue causes dilated, tortuous, thin-walled airways—the hallmark of bronchiectasis .

Evidence-Based Airway Clearance Therapy (ACT) Protocol

Daily airway clearance therapy (ACT) is the cornerstone of CF pulmonary preservation. The physical clearance of thick endobronchial secretions cannot occur effectively without prior biochemical hydration and enzymatic liquefaction of mucus. The Cystic Fibrosis Foundation (CFF) establishes a mandatory sequential order of administration for inhaled pulmonary therapies. Administering these medications out of sequence significantly blunts therapeutic efficacy and wastes high-cost therapies. Mandatory Sequential Order of Daily Respiratory Regimen:

  • ┌─────────────────────────────────────────────────────────────┐
  • │ STEP 1: Inhaled Bronchodilator │
  • │ (Albuterol 2.5 mg neb or 2-4 puffs MDI with spacer) │
  • │ ──► Relaxes bronchial smooth muscle; prevents bronchospasm │
  • └──────────────────────────────┬──────────────────────────────┘
  • ▼
  • ┌─────────────────────────────────────────────────────────────┐
  • │ STEP 2: Inhaled Hypertonic Saline 7% │
  • │ (4 mL nebulized via jet nebulizer) │
  • │ ──► Osmotically rehydrates airway surface liquid (ASL) │
  • └──────────────────────────────┬──────────────────────────────┘
  • ▼
  • ┌─────────────────────────────────────────────────────────────┐
  • │ STEP 3: Inhaled Dornase Alfa (Pulmozyme) │
  • │ (2.5 mg daily via dedicated jet nebulizer) │
  • │ ──► Cleaves extracellular neutrophil DNA; thins sputum │
  • └──────────────────────────────┬──────────────────────────────┘
  • ▼
  • ┌─────────────────────────────────────────────────────────────┐
  • │ STEP 4: Physical Airway Clearance Technique (ACT) │
  • │ (High-Frequency Chest Wall Oscillation vest / PEP / CPT) │
  • │ ──► Mobilizes and expectorates liquefied secretions │
  • └──────────────────────────────┬──────────────────────────────┘
  • ▼
  • ┌─────────────────────────────────────────────────────────────┐
  • │ STEP 5: Inhaled Antibiotics (ADMINISTERED LAST!) │
  • │ (Tobramycin, Aztreonam lysine, or Colistimethate) │
  • │ ──► Maximum deposition, penetration & mucosal residence │
  • └─────────────────────────────────────────────────────────────┘
  • Step 1: Inhaled Short-Acting Bronchodilator

Agent: Albuterol (salbutamol) 2.5 mg via jet nebulizer or 2 to 4 puffs (90 mcg/actuation) via metered-dose inhaler (MDI) with a valved holding chamber, administered 15 to 30 minutes prior to subsequent therapies.

Mechanism & Rationale: Stimulates β₂-adrenergic receptors on airway smooth muscle, triggering adenylate cyclase-mediated cAMP accumulation and bronchodilation. Pre-treatment opens obstructed lower airways to improve aerosol distribution of downstream agents and crucially prevents bronchospasm provoked by inhaled osmotic irritants (hypertonic saline).

Step 2: Inhaled Hypertonic Saline (7% NaCl)

Agent: 7% Sodium Chloride Inhalation Solution (4 mL nebulized twice daily via a rapid jet nebulizer; 3% NaCl may be utilized if 7% causes intolerable coughing or bronchospasm despite albuterol pre-treatment).

Mechanism & Rationale: Creates a steep osmotic gradient across the airway epithelium, drawing water from the submucosa and capillary beds into the airway surface liquid. This rehydrates the collapsed periciliary fluid layer, restores ciliary beat frequency, breaks ionic bonds within the mucin network, and stimulates cough reflex.

Step 3: Recombinant Human Deoxyribonuclease (Dornase Alfa / Pulmozyme)

Agent: Dornase alfa (Pulmozyme) 2.5 mg (one 2.5 mL ampule) nebulized once daily (some severe patients benefit from 2.5 mg twice daily) using an approved nebulizer system (e.g., Pari LC Plus with a compatible compressor such as Pari Proneb Ultra, or approved vibrating mesh nebulizers).

Mechanism & Rationale: Dornase alfa is a genetically engineered version of the human extracellular DNase I enzyme. It selectively cleaves phosphodiester bonds in high-molecular-weight extracellular neutrophil DNA without affecting human cellular intracellular genomic DNA. By depolymerizing massive DNA strands into small fragments, it dramatically reduces sputum viscoelasticity, cohesiveness, and adhesiveness within 30 to 60 minutes, converting tenacious gel-like plugs into mobile liquid secretions.

Compatibility & Storage Mandates:

DO NOT MIX: Dornase alfa must never be admixed or co-nebulized with any other medication in the nebulizer cup. Chemical incompatibilities, pH variations, and alterations in osmolarity cause immediate enzyme denaturing, precipitation, and loss of biological activity.

Storage: Dornase alfa is a biological protein that is highly thermolabile and light-sensitive. It must be refrigerated at 2°C to 8°C (36°F to 46°F) in its protective foil pouch. Ampules removed from refrigeration must be protected from intense light and heat and discarded if left at room temperature for >24 hours or if the solution appears cloudy or discolored.

Step 4: Airway Clearance Modality (ACT)

Modality: High-frequency chest wall oscillation (HFCWO / oscillating vest, typically 10–15 Hz for 20–30 minutes), positive expiratory pressure (PEP) mask, oscillating PEP (e.g., Flutter, Acapella, Aerobika), autogenic drainage, or manual chest physiotherapy (percussion and postural drainage).

Mechanism & Rationale: Once secretions are osmotically hydrated and enzymatically thinned, external oscillatory shearing forces loosen mucus from bronchial walls and propel it from small, peripheral bronchioles into larger central conduits, where it can be expectorated via huff-coughing.

Step 5: Inhaled Antimicrobials (Administered Strictly LAST)

Agents: Inhaled tobramycin (solution or dry powder), inhaled aztreonam lysine (Cayston), or colistimethate sodium.

Critical Timing Rationale: Inhaled antibiotics must always be administered LAST, AFTER the completion of airway clearance . If administered prior to clearance, the antibiotic deposits on top of thick, immobile mucus and is immediately coughed out and lost during chest physiotherapy. Administering to clean, cleared airways ensures deep alveolar and bronchiolar aerosol penetration, maximal direct contact with endobronchial Pseudomonas aeruginosa biofilm, and prolonged mucosal residence time without premature mechanical expulsion.

Airway Clearance Agent Dose & Route Pharmacologic Target Administration Sequence Critical Handling & Clinical Pearls

Albuterol 2.5 mg neb or 2–4 puffs MDI Airway β₂-adrenergic receptors Step 1 (First) Relaxes smooth muscle; prevents hypertonic saline-induced bronchospasm; wait 15 min prior to Step 2.

Hypertonic Saline (7%) 4 mL neb BID Osmotic water gradient across epithelium Step 2 (Second) Osmotically hydrates ASL; must be preceded by bronchodilator; step down to 3% if 7% induces cough/wheezing.

Dornase Alfa (Pulmozyme) 2.5 mg neb daily Extracellular neutrophil DNA phosphodiester bonds Step 3 (Third) Cleaves neutrophil DNA NETs; do NOT mix with other drugs in cup; store in fridge (2–8°C); light sensitive.

Chest Physiotherapy / Vest 20–30 min session BID Mechanical shearing of mucus Step 4 (Fourth) Physically dislodges thinned secretions; perform active huff-cough maneuvers to expectorate sputum.

Inhaled Antibiotics (TOBI, Cayston) Weight/drug specific neb/DPI Bacterial ribosomal / cell wall targets Step 5 (LAST) Must be given to cleared lungs; prevents coughing out drug; maximizes tissue residence and antimicrobial efficacy.

Practice Pearls & BCPPS Exam Traps

Exam Trap 1: Never administer inhaled antibiotics prior to chest physiotherapy or airway clearance. The exam frequently tests a scenario where a nurse or parent gives tobramycin before the vest session to "save time." This is an egregious error; the antibiotic will be coughed into the sputum cup rather than penetrating the airway epithelium.

Exam Trap 2: Do not co-mix dornase alfa with hypertonic saline, albuterol, or antibiotics in a single nebulizer cup. Dornase alfa is an enzyme; any alteration in pH or ionic strength leads to protein aggregation and irreversible enzymatic denaturation.

Diagnostic Trap: A sweat chloride of 45 mmol/L in an infant is NOT negative. Values between 30 and 59 mmol/L are intermediate/borderline and require aggressive repeat sweat testing and full CFTR gene sequencing.